Factores de riesgo para cáncer de cuello uterino

  • Ricardo Ortiz Serrano
  • Claudia Janeth Uribe Pérez
  • Luis Alfonso Díaz Martínez
  • Yuriko Rafael Dangond Romero

Resumen

El cáncer del cuello uterino es una de las neoplasias malignas de mayor incidencia y mortalidad entre las mujeres de todas partes del mundo, hallazgo que resulta paradójico si se tiene en cuenta que el cuello uterino es de fácil acceso y existen estrategias debidamente probadas que permiten un diagnóstico y tratamiento precoz. En esta revisión se describe detalladamente la epidemiología del cáncer del cuello uterino, en especial los factores de riesgo relacionados con la génesis de la neoplasia y su diagnóstico tardío.

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Ricardo Ortiz Serrano
Facultad de Medicina, Universidad Autónoma de Bucaramanga, Bucaramanga.
Claudia Janeth Uribe Pérez
 Facultad de Medicina, Universidad Autónoma de Bucaramanga, Bucaramanga.
Luis Alfonso Díaz Martínez
Facultad de Medicina, Universidad Autónoma de Bucaramanga, Bucaramanga.
Yuriko Rafael Dangond Romero
Facultad de Medicina, Universidad Autónoma de Bucaramanga, Bucaramanga.

Referencias bibliográficas

La carga de la enfermedad en Colombia. Bogotá: Ministerio de Salud; 1994.

Haddad N, da Silva MB. Mortalidade por neoplasmas em mulheres em idade reprodutiva - 15 a 49 anos - no estado de São Paulo, Brasil, de 1991 a 1995. Rev Assoc Med Bras 2001;47:221-30.

Bosch FX, Lorincz A, Muñoz N, Meijer CJL, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.

Medina MR. Atlas de mortalidad por cáncer en Colombia 1990. Bogotá: Instituto Nacional de Cancerología; 1994.

Capurro I, Rojo JA, Pino T, Vásquez C, Garay J, Venegas M. Programa de detección y control de cáncer de cuello uterino en servicio salud Araucania Sur. Rev Chil Obstet Ginecol 2002;67:114-20.

Wright TC, Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ; ASCCP-Sponsored Consensus Conference. 2001 consensus guidelines for the management of women with cervical cytology abnormalities. JAMA 2002;287:2120-9.

Shanta V, Krishnamurthi S, Gajalakshmi CK, Swaminathan R, Ravichandran K. Epidemiology of cancer of cervix: global and national perspective. J Indian Med Assoc 2000;98:49-52.

Sánchez V, Izquierdo A, Beltrán M, Viladiu P. Epidemiología del cáncer invasor de cerviz en el àrea sanitaria de Girona durante el período 1980-1989. Registro poblacional de cáncer de Gerona. Rev Esp Salud Publica 1997;71:19-26.

Sherris J, Herdman C, Elias C. Beyond our borders. Cervical cancer in the developing world. West J Med 2001;175:231-3.

Registro Poblacional de Cáncer del Área Metropolitana de Bucaramanga. Incidencia de cáncer en el Área Metropolitana de Bucaramanga, 2000-2001. UNAB; 2003.

Viikki M, Pukkala E, Hakama M. Risk of cervical cancer after a negative Pap smear. J Med Screen 1999;6:103-7.

Hernández-Avila M, Lazcano-Ponce EC, Alonso de Ruiz P, López-Carrillo L, Rojas R. Evaluación del programa de detección oportuna de cáncer de cuello uterino en la ciudad de México. Un estudio epidemiológico de casos y controles con base poblacional. Gac Méd Méx 1994;130:201-9.

Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ 2001;79:954-62.

Gómez J. Costos y calidad de la prueba de detección oportuna del cáncer cervicouterino en una clínica y en una organización no gubernamental. Salud pública Méx 2001;43:279-88.

Invasive cervical cancer amog hispanic and non-hispanic women – United States, 1992-1999. MMWR Morb Mortal Wkly Rep 2002;51:1067-70.

Hakama M. Trends in the incidence of cervical cancer in the Nordic countries. In: Magnus K (ed). Trends in cancer incidence: causes and practical implications. Washington: Hemisphere Pub. Corp.; 1982. p. 279-92.

Sigurdson K, Adalsteinsson S, Ragnarsson J. Trends in cervical and breast cancer in Iceland. A statistical evaluation of trends in incidence and mortality for the period 1955-1989. Their relation to screening and prediction to the year 2000. Int J Cancer 1991;48:523-8.

Ehrmann RL. Benign to malignant progression in cervical squamous epithelium. New York: Igauku-Shoin; 1994.

Raab SS, Steiner AL, Hornberger J. The cost-effectiveness of treating women with a cervical vaginal smear diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1998;179:411-20.

Disaia PJ, Creasman WT. Clinical gynecologic oncology. 5th ed. St. Louis: Mosby; 1999.

Mandelblatt JS, Kanetsky P, Eggert L, Gold K. Is HIV infection a cofactor for cervical squamous cell neoplasia? Cancer Epidemiol Biomarkers Prev 1999;8:97-106.

Wang SS, Wheeler CM, Hildesheim A, Schiffman M, Herrero R, Bratti MC, et al. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis 2001;184:1310-4.

Apgar BS, Brotzman G. HPV testing in the evaluation of the minimally abnormal Papanicolau smear. Am Fam Physician 1999;59:2794-801.

Sellors JW, Mahony JB, Kaczorowski J, Lytwyn A, Bangura H, Chong S, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. CMAJ 2000;165:503-8.

Sellors JW, Lorincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. CMAJ 2000;165:513-8.

Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Eng J Med 1998;338:423-8.

Lytwyn A, Sellors JN. Sexually transmitted human papillomavirus: current concepts and control issues. Can J Hum Sex 1997;6:113-26.

Hart KW, Williams OM, Thelwell N, Fiander AN, Brown T, Borysiewicz LK, et al. Novel method for detection, typing and quantification of human papillomaviruses in clinical samples. J Clin Microbiol 2001;39:3204-12.

Molano M, Posso HJ, Weiderpass E, van den Brule AJ, Ronderos M, Franceshi S, et al. Prevalence and determinants of HPV infection among Colombian women with normal citology. Br J Cancer 2002;87:324-33.

Nonenmacher B, Breitnebach V, Villa LL, Prolla JC, Bozzetti MC. Identificação do papilomavírus humano por biología molecular em mulheres assintomáticas. Rev Saúde Pública 2002;36:59-100.

Flores Y, Shah K, Lazcano E, Hernández M, Bishai D, Ferris D, et al. Design and methods for the evaluation of an HPV-based cervical cancer screening strategy in México: the Morelos HPV Study. Salud pública Méx 2002;44:335-44.

Meijer CJ, Snijders PJ, van den Burle AJ. Screening for cervical cancer: shuold we test for infection with high-risk HPV? CMAJ 2000;163:535-8.

Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.

Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002;360:228-9.

Varghese C, Amma NS, Chitrathara K, Dhakad N, Rani P, Malathy L, et al. Risk factors for cervical dysplasia in Kerala, India. Bull World Health Organ 1999;77:281-3.

Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106-14.

Bosch FX, Manos MM, Muñoz M, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (I BSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.

de San José S, Palacio V, Tafur LA, Vázquez S, Espitia VE, Vázquez F, et al. Prostitution, HIV, and cervical neoplasia: a survey in Spain and Colombia. Cancer Epidemiol Biomarkers Prev 1993;2:531-5.

Tran-Thanh D, Provecher D, Koushik A, Duarte-Franco E, Kessous A, Drouin P, et al. Herpes simplex virus type II is not a cofactor to human papillomavirus in cancer of the uterine cervix. Am J Obstet Gynecol 2003;188:129-34.

Munoz N, Kato I, Bosch FX, Eluf-Neto J, de San Jose S, Ascunce N, et al. Risk factor for HPV detection in middle-age women. Sex Transm Dis 1996;23:504-10.

Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikaheimo I, et al. Serotypes of Chlamydia trachomatis and risk of development of cervical squamous cell carcinoma. JAMA 2001;285:47-51.

Ellerbrock TV, Chiasson MA, Bush TJ, Sun XW, Sawo D, Brudney K, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283:1031-7.

Castañeda-Iñiguez MS, Toledo-Cisneros R, Aguilera-Delgadillo M. Factores de riesgo para cáncer cervicouterino en mujeres de Zacatecas. Salud Pública Méx 1998;40:330-8.

Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002;359:1093-101.

Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA 2000;284:706-12.

Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002;359:1085-92.

Mohar A, Frías-Mendivil M, Suchil-Bernal L, Mora-Macías T, de la Garza JG. Epidemiología descriptiva del cáncer en el Instituto Nacional de Cancerología de México. Salud Pública Méx 1997;39:253-8.

Hasenyager C. Knowledge of cervical cancer screening among women attending a university health center. J Am Coll Health 1999;47:221-4.

Fernández ME, Tortolero-Luna G, Gold RS. Mammography and Pap test screening among low-income foreign-born Hispanic women in the USA. Cad Saúde Pública 1998; 14:133-47.

Lorant V, Boland B, Humblet P, Deliege D. Equity in prevention and health care. J Epidemiol Community Health 2002;56:510-6.

Benia W, Tellecha G. Estudio de los factores de riesgo para cáncer de mama y cuello uterino en mujeres usuarias de tres policlínicas barriales de Montevideo: 1997. Rev Med Uruguay 2000;16:101-16.

Lindau ST, Tomori C, Lyons T, Langseth L, Benett CL, Garcia P. The association of heath literacy with cervical cancer prevention knowledge and health behaviors in multiethnic cohort women. Am J Obstet Gynecol 2002;186:938-43.

McKee MD, Lurio J, Marantz P, Burton W, Mulvihill M. Barriers to follow-up of abnormal Papanicolau smears in an urban community health center. Arch Fam Med 1999;8:129-34.

Marteau TM, Senior V, Sasieni P. Women`s understanding of a "normal smear test result": experimental questionnaire based study. BMJ 2001;322:526-8.

Hewitt M, Devesa S, Breen N. Papanicolau test use among reproductive-age women at high risk for cervical cancer: analyses of the 1995 National Survey of Family Growth. Am J Public Health 2002;92:666-9.

Aguilar-Pérez JA, Leyva-López AG, Angulo-Nájera D, Salinas A, Lazcano-Ponce EC. Tamizaje de cáncer cervical: conocimiento de la utilidad y uso de citología cervical en México. Rev Saúde pública 2003;37:100-6.

Lamadrid S. Aspectos socio-culturales de la sexualidad como factores obstaculizantes de la prevención secundaria del cáncer cérvico uterino. Cad Saúde Púb 1998;14 Sup 1:33-40.

Lazcano-Ponce EC, Rascon-Pacheco RA, Lozano-Ascencio R, Velasco-Mondragón HE. Mortality from carcinoma of the uterine cervix in México. Acta Cytol 1996;40:506-12.

Lazcano-Ponce EC, Alonso de Ruiz P, Lopez-Carrillo L, Najera-Aguilar P, Avila-Ceniceros R, Escandon-Romero C, et al. Validity and reproducibility of cytologic diagnosis in a sample of cervical cancer screening centers in Mexico. Acta Cytol 1997;41:227-84.

República de Colombia. Ministerio de Salud. Decreto 2309 de Octubre 15 de 2002.

Arillo-Santillán E, Lazcano-Ponce E, Peris M, Salazar-Martínez E, Salomón-Castro J, Alonso-De Ruiz P. El conocimiento de profesionales de la salud sobre la prevención del cáncer cervical. Alternativas de educación médica. Salud Pública Méx 2000;42:34-42.

Tovar-Guzman V, Hernández-Giron C, Lazcano-Ponce E, Romineu I, Hernández M. Breast cancer in Mexican women: an epidemiological study with cervical cancer control. Rev Saúde Pública 2000;24:113-9.

Pinho AA, de Mattos MC. Validade da citologia cervicovaginal na detecção de lesões pré-neoplásicas e neoplásicas de colo de útero. J Brasil Patol Med Lab 2002;38:225-31.

Sawaya GF, Brown AD, Washington AE, Garber AM. Clinical practice. Current approaches to cervical-cancer screening. N Eng J Med 2001;344:1603-7.

Sherlaw-Johnson C, Gallivan S, Jenkins D. Withdrawing low risk women from cervical screening programmes: mathematical modeling study. BMJ 1999;318:356-61.

Selvaggi SM. Implications of low diagnostic reproducibility of cervical cytologic and histologic diagnosis. JAMA 2001;285:1506-7.

Pinto AP, Tulio S, Cruz OR. Co-factores do HPV na oncogênese cervical. Rev Assoc Med Brasil 2002;48:73-8.

Adad SJ, Souza MAH, Etchebehere RM, Sandanha JC, Falco VAA, Murta EFC. Cyto-histological correlation of 219 patients submitted to surgical treatment due to diagnosis of cervical intraepithelial neoplasia. S Paulo Med J 1999;117:81-4.

Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytology and histologic interpretations. Realistic estimates from the USCUS-LSIL Triage Study. JAMA 2001;285:1500-5.

Miller AB. Failures of cervical cancer screening. Am J Public Health 1995;85:761.

Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.

Stoler MH. New Bethesda terminology and evidence-based management guidelines for cervical cytology findings. JAMA 2002;287:2140-1.

Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Eng J Med 1996;334:1030-7.

Lonky NM, Sadeghi M, Tsadik GW, Petitti D. The clinical significance of the poor correlation of cervical dysplasia and cervical malignancy with referral cytologic results. Am J Obstet Gynecol 1999;181:560-6.

Parashari A, Singh V, Sehgal A, Satyanarayana L, Sodhani P, Gupta MM. Low-cost technology for screening uterine cervical cancer. Bull World Health Organ 2000;78:964-7.

Organización Panamericana de la Salud. Prevención clínica. Guía para médicos. Publicación científica Nº 568. Washington: OPS; 1998.

University of Zimbabwe/JHPIEGO Cervical Cancer Project. Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. Lancet 1999;353:869-73.

Publicado
2004-06-30
Cómo citar
1.
Ortiz Serrano R, Uribe Pérez CJ, Díaz Martínez LA, Dangond Romero YR. Factores de riesgo para cáncer de cuello uterino. Rev. Colomb. Obstet. Ginecol. [Internet]. 30 de junio de 2004 [citado 29 de noviembre de 2021];55(2):146-60. Disponible en: https://revista.fecolsog.org/index.php/rcog/article/view/602
Sección
Artículo de Revisión